Latest Intellectual Property News

BrainChip Holdings reports a significant revenue surge and reduced losses in H1 2025, underpinned by new contracts, strategic collaborations, and an expanded funding agreement.

Orbital Corporation reveals a strategic pivot amid evolving US drone policies, with a new management team driving growth beyond Boeing Insitu. FY25 guidance shows revenue decline but promising new contracts.

NRW Holdings reported a robust 12.2% revenue increase to $3.3 billion in FY25, offsetting a significant $110.5 million impairment linked to OneSteel. Strong Civil and MET segment growth underpinned solid earnings despite Queensland weather challenges.

Tryptamine Therapeutics has secured an exclusive agreement with leading neuroscientists to develop a novel EEG-based brain entropy biomarker aimed at enhancing precision psychiatry for its psychedelic drug TRP-8803.

IPH Limited reported a solid 16.5% revenue increase to $710.3 million for FY25, driven by strategic acquisitions in Canada and strong organic growth in Asia and ANZ. Despite ongoing delays at the Canadian Intellectual Property Office, the company achieved higher earnings and dividends, setting the stage for further operational efficiencies and technology investments.

IPH Limited reported a 13.2% rise in net profit after tax to $68.8 million for FY25, driven by strategic acquisitions in Canada and organic growth across Asia-Pacific. Revenue surged 16.5% to $710.3 million despite inflationary pressures and operational challenges.

Li-S Energy Limited reported a $6.41 million net loss for FY25 while making significant strides in commercialising its lithium-sulfur battery technology, including commissioning new production facilities and securing key strategic partnerships.

IPH Limited reported a robust FY25 with revenue rising 16.6% to $710.3 million and net profit after tax up 13.2% to $68.8 million, driven by strategic acquisitions and a pivot towards organic growth and AI integration.

Prescient Therapeutics reported an 11.1% reduction in net loss for FY2025, progressing its lead candidate PTX-100 into Phase 2a trials with FDA Fast Track and Orphan Drug designations, supported by a recent $9.8 million capital raise.

Genetic Technologies Limited has emerged from voluntary administration following a strategic asset sale and is now pursuing recapitalisation and acquisitions to restore its market position.

Genetic Technologies Limited reports a 36% increase in half-year losses amid voluntary administration, followed by a recapitalisation and sale of core assets. The company pivots towards new financial services acquisitions under fresh leadership.

Beam Communications finalizes the independent valuation of its Zoleo Inc. joint venture stake at US$13.7 million and confirms plans to return capital to shareholders.